Pelthos Therapeutics Earnings Call Shows Strong Launch

Pelthos Therapeutics Inc. ((PTHS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Pelthos Therapeutics’ latest earnings call painted a cautiously optimistic picture, with management emphasizing strong prescription and revenue growth alongside broader payer access and improved liquidity. While the company is still losing money and facing rising operating and financing costs, executives framed these as deliberate investments to cement early launch momentum and pave the way for future product introductions.

Strong Prescription and Revenue Growth

Prescribed units jumped 25% quarter over quarter, rising from 6,312 in Q4 2025 to 7,884 in Q1 2026 as Pelthos’ flagship therapy continued to gain traction with prescribers. Net product revenue climbed 17% over the same period, moving from $9.1 million to $10.7 million and lifting cumulative launch revenue over three quarters to $26.9 million.

Continued Month-to-Month Momentum

Management highlighted that growth is not only quarterly but also visible in more granular data, with prescribed units up 14.1% month to month as March’s 3,309 prescriptions rose to 3,776 in April. Weekly trends also set new highs, with 917 prescribed units for the week ending May 1 underscoring the acceleration heading into the second quarter.

PBM Contract and Prescriber Expansion

A major pharmacy benefit manager contract signed in December 2025 emerged as a key catalyst, as units dispensed within that PBM doubled and prescribers under that umbrella rose 121%. Companywide, total unique prescribers expanded from 2,377 to 3,228, suggesting growing clinical acceptance and a widening base of doctors writing repeat scripts.

Broad Payer Coverage and Favorable Access

Pelthos underscored payer wins, citing coverage for 59% of commercial plans and 99% of Medicaid, which materially reduces access barriers for patients. The company also reported shorter prior authorization processing times and strong uptake of its co‑pay card program, contributing to a favorable gross‑to‑net rate of 29.1% in Q1 even though management expects that figure to drift higher.

Sales Team Expansion and Early ROI

To support the launch, Pelthos expanded its commercial field force from 50 to 64 territory managers, and early data suggest the move is paying off. The company noted that many of the newly added territories have already shown rapid prescription growth, in some cases generating enough volume to cover their associated sales costs within a short period of time.

Pipeline and Product Launch Planning

Beyond the current product, Pelthos is preparing for the launch of two complementary FDA‑approved therapies, XEPI and XEGLYZE, now in manufacturing and launch planning. XEPI is targeted for early 2027 and XEGLYZE for mid‑2027, and both are expected to leverage the existing salesforce, which management argues should limit incremental overhead and enhance operating leverage over time.

Improved Liquidity and Working Capital

On the balance sheet, Pelthos boosted liquidity by closing a $50 million term debt facility and drawing $30 million, with the Horizon financing adding roughly $27.5 million of net cash. As of March 31, 2026, the company reported cash of $32 million and working capital of $44.8 million, up from $27.4 million at the end of Q4 2025, bolstering confidence in its runway.

Launch Traction and Commercial Engagement

Since the July 2025 launch, more than 20,000 units have been dispensed, and management highlighted strong qualitative feedback from health care providers, patients and caregivers. The company is leaning on digital marketing as well, pointing to a YouTube commercial with more than 6.7 million views and the rollout of new testimonial content designed to deepen engagement.

Continued Losses and Negative EBITDA

Despite solid top‑line progress, Pelthos remains unprofitable, reporting a Q1 2026 net loss of $10.2 million, though that marked a sharp improvement from the $21.7 million loss in Q4 2025. Adjusted EBITDA stayed negative at $8.0 million versus a negative $7.6 million in the prior quarter, highlighting that profitability remains a medium‑term goal rather than an imminent milestone.

Rising SG&A and Interest Expense

Operating expenses continued to climb, with SG&A rising 14% quarter over quarter to $21.1 million, driven by higher personnel costs, marketing and commercial investments plus regulatory and manufacturing spending. On a cash basis excluding royalties, SG&A was about $16.9 million versus $14.7 million, while interest expense nearly doubled from $1.3 million to $2.4 million as the new debt facility began to flow through the income statement.

Gross-to-Net Pressure Outlook

The company cautioned that its current 29.1% gross‑to‑net benefit is unlikely to persist, as Pelthos expects GTN to move into the mid‑30% range over time. That shift would effectively reduce net revenue per prescription, reflecting deeper discounts and rebates as access expands, and investors will be watching whether volume gains can offset this pressure.

Inventory Accounting and One-Time Write-offs

Management also walked through several accounting items, including Q4 2025 inventory write‑offs of $121,000 tied to capitalized process validation. The stepped‑up fair value of finished goods from the July 2025 merger is expected to be consumed by late summer 2026, and the stepped‑up active ingredient basis over roughly 12 to 15 months, which could delay cost‑of‑goods normalization despite improving manufacturing efficiency.

No Formal Revenue/Earnings Guidance

While Pelthos remains vocal about its commercialization plans, the company has not provided formal revenue or earnings targets, leaving near‑term financial visibility somewhat constrained for investors. Management instead points to operational milestones, such as prescription growth, payer coverage and pipeline timing, as the key indicators of progress in the absence of specific numeric guidance.

Operational Disruptions and Seasonality

Executives reminded listeners that short‑term prescribing trends can be influenced by external factors like severe weather and seasonal office closures, which impacted January volumes. They also flagged ongoing payer contracting and access management as critical operational tasks, underscoring that execution risk remains as the company scales its commercial footprint.

Forward-Looking Guidance and Outlook

Looking ahead, Pelthos expects gross‑to‑net to move to the mid‑30% range and normalized per‑unit cost of goods to fall to a mid‑single‑digit percentage of current list prices once stepped‑up inventory is fully consumed, likely starting after late summer 2026. Management reaffirmed confidence in the revenue trajectory and liquidity position, supported by rising prescription volumes, expanding sales coverage and the planned 2027 launches of XEPI and XEGLYZE, even as quarterly SG&A is expected to remain volatile.

Pelthos’ earnings call ultimately sketched a story of solid launch execution tempered by the realities of an early‑stage commercial biopharma still burning cash. For investors, the key watchpoints will be whether prescription momentum can outpace rising discounts and expenses, and how efficiently the company can leverage its infrastructure as new products arrive to drive a path toward sustainable profitability.